+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hematologic Malignancies Testing Market by Technology, Application, End User, Sample Type, Test Mode - Global Forecast to 2030- Product Image
Hematologic Malignancies Testing Market by Technology, Application, End User, Sample Type, Test Mode - Global Forecast to 2030- Product Image
Sale

Hematologic Malignancies Testing Market by Technology, Application, End User, Sample Type, Test Mode - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924675
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The hematologic malignancies testing market is poised for robust evolution, shaped by advancing diagnostics, regulatory change, and expanding adoption across healthcare systems. Senior decision-makers are navigating a landscape where technology integration, policy shifts, and operational pressures converge to influence laboratory strategies and patient outcomes.

Market Snapshot: Hematologic Malignancies Testing Market Overview

The Hematologic Malignancies Testing Market grew from USD 3.60 billion in 2024 to USD 3.90 billion in 2025. It is expected to continue growing at a CAGR of 7.90%, reaching USD 5.69 billion by 2030. This trajectory reflects increased demand for precision diagnostics, driven by the rising global incidence of leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes. Adoption of next-generation sequencing, flow cytometry, and advanced immunohistochemistry is pivotal in transforming both clinical workflows and patient management. Laboratories worldwide are elevating operational capabilities to keep pace with the complex, evolving market environment.

Scope & Segmentation

This report provides comprehensive coverage across key market segments, enabling targeted analysis and strategic planning.

  • Technology: Cytogenetics, including fluorescence in situ hybridization and karyotyping; Flow Cytometry; Immunohistochemistry, in liquid-based and tissue-based formats; Molecular Diagnostics, spanning fluorescence in situ hybridization, next-generation sequencing, and polymerase chain reaction.
  • Application: Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes.
  • End User: Academic & Research Institutes, Hospitals & Clinics, Reference Laboratories.
  • Sample Type: Blood, Bone Marrow.
  • Test Mode: Laboratory Based, Point of Care.
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and others), Asia-Pacific (including China, India, Japan, Australia, and more).
  • Company Coverage: F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Siemens Healthineers AG, QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc.

Key Takeaways for Decision-Makers

  • Advanced molecular testing and digital solutions are accelerating turnaround times and enhancing risk stratification in hematologic malignancies.
  • The market reflects strong demand for flexible diagnostics, enabling personalized therapy and improved patient stratification, aligned with trends in precision medicine.
  • Regional and policy diversity requires tailored strategies—healthcare infrastructure, reimbursement dynamics, and regulatory harmonization are shaping adoption and access.
  • Coordination between centralized labs, hospitals, and reference laboratories presents new operational opportunities, especially as point-of-care technologies integrate into mainstream practice.
  • Collaboration between diagnostics manufacturers and academic partners is vital for innovation, ensuring the translation of new biomarkers and digital approaches into clinical care.
  • Providers must continuously adapt to complex supply chain scenarios to maintain both cost efficiency and quality amid external pressures.

Tariff Impact: Navigating the 2025 U.S. Tariffs

The introduction of U.S. tariffs on diagnostics-related reagents and equipment in 2025 has increased cost pressures for laboratories, prompting a strategic rethink in procurement and supply chain models. Institutions are responding by diversifying suppliers, establishing regional production, and adopting lean inventory approaches where possible. Manufacturers are investing in local fabrication capacity and aligning with evolving regulatory requirements to maintain competitiveness. These shifts are influencing both operational expenditures and the speed with which new technologies can be adopted, underscoring the importance of agile sourcing and cross-industry collaboration.

Methodology & Data Sources

Analytical findings are based on a blend of primary research interviews with experts in hematopathology, molecular diagnostics, and policy, coupled with secondary research from scientific publications, regulatory documents, financial filings, and industry white papers. Competitive landscape analysis leverages SWOT, PESTLE, and benchmarking frameworks, validated by advisory board review and robust data triangulation for reliable insights.

Why This Report Matters

  • Enables senior leaders to assess market dynamics, emerging technologies, and competitive positioning for informed strategy development.
  • Helps organizations benchmark their offerings, investment priorities, and geographic focus against evolving regulatory and reimbursement landscapes.
  • Supports proactive risk management by providing an actionable view of tariff impacts, supply chain vulnerabilities, and opportunities for operational optimization.

Conclusion

The hematologic malignancies testing market is advancing towards more integrated, innovative, and adaptable diagnostics solutions. Stakeholders who align technical capability, strategic agility, and robust partnerships will be best positioned for continued growth and leadership in this critical sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hematologic Malignancies Testing Market, by Technology
8.1. Introduction
8.2. Cytogenetics
8.2.1. Fluorescence in Situ Hybridization
8.2.2. Karyotyping
8.3. Flow Cytometry
8.4. Immunohistochemistry
8.4.1. Liquid Based
8.4.2. Tissue Based
8.5. Molecular Diagnostics
8.5.1. Fluorescence in Situ Hybridization
8.5.2. Next Generation Sequencing
8.5.3. Polymerase Chain Reaction
9. Hematologic Malignancies Testing Market, by Application
9.1. Introduction
9.2. Leukemia
9.3. Lymphoma
9.4. Multiple Myeloma
9.5. Myelodysplastic Syndromes
10. Hematologic Malignancies Testing Market, by End User
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Hospitals & Clinics
10.4. Reference Laboratories
11. Hematologic Malignancies Testing Market, by Sample Type
11.1. Introduction
11.2. Blood
11.3. Bone Marrow
12. Hematologic Malignancies Testing Market, by Test Mode
12.1. Introduction
12.2. Laboratory Based
12.3. Point of Care
13. Americas Hematologic Malignancies Testing Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Hematologic Malignancies Testing Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Hematologic Malignancies Testing Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche AG
16.3.2. Abbott Laboratories
16.3.3. Danaher Corporation
16.3.4. Thermo Fisher Scientific Inc.
16.3.5. Becton, Dickinson and Company
16.3.6. Siemens Healthineers AG
16.3.7. QIAGEN N.V.
16.3.8. Illumina, Inc.
16.3.9. Bio-Rad Laboratories, Inc.
16.3.10. Myriad Genetics, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET MULTI-CURRENCY
FIGURE 2. HEMATOLOGIC MALIGNANCIES TESTING MARKET MULTI-LANGUAGE
FIGURE 3. HEMATOLOGIC MALIGNANCIES TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 54. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 55. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 56. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 57. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 58. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 63. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 65. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 103. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 105. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 106. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 107. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 110. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 111. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 113. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 114. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 115. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 118. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 127. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 128. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 129. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 130. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 131. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 134. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 135. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 137. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 138. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 139. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 142. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 167. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 168. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 169. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 170. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 171. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 174. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 183. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 184. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 185. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 186. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 187. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 190. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 191. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 192. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 193. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 194. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 195. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 198. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 215. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 218. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 219. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 222. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 224. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 226. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 227. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 230. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 239. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 240. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 241. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 242. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 243. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 246. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 247. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 248. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 249. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 250. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 251. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 254. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 272. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 273. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 274. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 275. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 276. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 277. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 279. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 280. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 281. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 282. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 283. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 284. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 287. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 288. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 289. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 290. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 291. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 292. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 295. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hematologic Malignancies Testing market report include:
  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • Siemens Healthineers AG
  • QIAGEN N.V.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics, Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.9 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.69 Billion
Compound Annual Growth Rate7.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Hematologic Malignancies Testing Market - A Global and Regional Analysis: Focus on Product, Platform, Disease, End User, and Region - Analysis and Forecast, 2024-2033 - Product Image

Hematologic Malignancies Testing Market - A Global and Regional Analysis: Focus on Product, Platform, Disease, End User, and Region - Analysis and Forecast, 2024-2033

  • Report
  • 258 Pages
  • Global
From
Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Europe Hematologic Malignancies Testing Market, By Country, Competition, Forecast and Opportunities, 2020-2030F - Product Image

Europe Hematologic Malignancies Testing Market, By Country, Competition, Forecast and Opportunities, 2020-2030F

  • Report
  • 133 Pages
  • Europe
From
Europe Hematologic Malignancies Testing Market: Focus on Product, Platform, Disease, End User, and Country - Analysis and Forecast, 2024-2033 - Product Image

Europe Hematologic Malignancies Testing Market: Focus on Product, Platform, Disease, End User, and Country - Analysis and Forecast, 2024-2033

  • Report
  • 100 Pages
  • Europe
From
Hematologic Malignancies Detection Market Report 2025 - Product Image

Hematologic Malignancies Detection Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.